• Adjusted EPS: $2.80 vs. $2.76 expected
• Revenue: $24.0B vs. $23.76B expected
• Net Earnings: $5.15B (+91% YoY)
• Reported EPS: $2.12 (+91% YoY)
• Innovative Medicine Sales: $15.56B (+6.8% YoY)
• MedTech Sales: $8.43B (+6.8% YoY)
• Full-Year Sales Outlook: Raised to ~$93.7B (midpoint +5.7%)
• FY Adjusted EPS Guidance: Reaffirmed at $10.85
Johnson & Johnson delivered another solid quarter, with both top- and bottom-line results surpassing expectations. Growth was driven by oncology (Darzalex, Carvykti), immunology (Tremfya), and MedTech innovations (Abiomed, Shockwave). The company also highlighted several key FDA approvals, including INLEXZO for bladder cancer and TREMFYA in ulcerative colitis.